Weight Loss Results: What the Data Shows When it comes to shedding pounds, injectable GLP-1s deliver superior results based on extensive clinical trials: Injectable semaglutide (Wegovy ) : 15-17% average body weight loss Injectable tirzepatide (Mounjaro /Zepboun d) : Up to 22.5% average body weight loss FDA-approved oral semaglutide: 13.6-16.6% average body weight loss Compounded ODT formulations : No published clinical trial data available A real-world comparison study found that patients on injectable semaglutide lost 1.62kg more than those on FDA-approved oral semaglutide over 26 weeks, which was not significant
Annals of dermatology , 28 (4), 438.
8 Agency EM
This means users can get more of the nutrients they need without taking multiple doses
[2] [3] These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)with tirzepatide being a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 agonist
It may also be affected by dehydration, reduced food intake, low fiber intake, other medications, or underlying health conditions